Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Wood

Showing results (201-210 of 369) with videos related to

Pageof 37
Sort By:
Lancet (London, England)|July 20, 2010
Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmesMargaret May, Andrew Boulle, Sam Phiri, et al.
Open Forum Infectious Diseases|July 7, 2017
Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South AfricaA David Paltiel, Amy Zheng, Milton C Weinstein, et al.
BMC Infectious Diseases|July 18, 2008
Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort studyKatherine L Fielding, Salome Charalambous, Amy L Stenson, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|July 27, 2011
Loss to follow-up in a community clinic in South Africa--roles of gender, pregnancy and CD4 countBingxia Wang, Elena Losina, Ruth Stark, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 1, 2006
CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatmentCharles B Holmes, Robin Wood, Motasim Badri, et al.
The Journal of Infectious Diseases|November 8, 2017
Drivers of Tuberculosis TransmissionBarun Mathema, Jason R Andrews, Ted Cohen, et al.
Plos Medicine|January 7, 2011
Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysisRochelle P Walensky, Robin Wood, Andrea L Ciaranello, et al.
African Health Sciences|October 26, 2005
Socio-behaviour challenges to phase III HIV vaccine trials in Sub-Saharan AfricaJoalida Smit, Keren Middelkoop, Landon Myer, et al.
Plos Medicine|August 11, 2012
Feasibility, yield, and cost of active tuberculosis case finding linked to a mobile HIV service in Cape Town, South Africa: a cross-sectional studyKatharina Kranzer, Stephen D Lawn, Gesine Meyer-Rath, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 29, 2004
Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavirRobin Wood, Praphan Phanuphak, Pedro Cahn, et al.
Pageof 37

Showing results (201-210 of 369) with videos related to

Sort By:
Pageof 37
Lancet (London, England)|July 20, 2010
Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmesMargaret May, Andrew Boulle, Sam Phiri, et al.
Open Forum Infectious Diseases|July 7, 2017
Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South AfricaA David Paltiel, Amy Zheng, Milton C Weinstein, et al.
BMC Infectious Diseases|July 18, 2008
Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort studyKatherine L Fielding, Salome Charalambous, Amy L Stenson, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|July 27, 2011
Loss to follow-up in a community clinic in South Africa--roles of gender, pregnancy and CD4 countBingxia Wang, Elena Losina, Ruth Stark, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 1, 2006
CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatmentCharles B Holmes, Robin Wood, Motasim Badri, et al.
The Journal of Infectious Diseases|November 8, 2017
Drivers of Tuberculosis TransmissionBarun Mathema, Jason R Andrews, Ted Cohen, et al.
Plos Medicine|January 7, 2011
Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysisRochelle P Walensky, Robin Wood, Andrea L Ciaranello, et al.
African Health Sciences|October 26, 2005
Socio-behaviour challenges to phase III HIV vaccine trials in Sub-Saharan AfricaJoalida Smit, Keren Middelkoop, Landon Myer, et al.
Plos Medicine|August 11, 2012
Feasibility, yield, and cost of active tuberculosis case finding linked to a mobile HIV service in Cape Town, South Africa: a cross-sectional studyKatharina Kranzer, Stephen D Lawn, Gesine Meyer-Rath, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 29, 2004
Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavirRobin Wood, Praphan Phanuphak, Pedro Cahn, et al.
Pageof 37